XML 54 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Payments - 2017 Share Incentive Plan (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
Dec. 31, 2018
tranche
Fair Value Assumptions          
Expected volatility (as a percent)     77.30%    
Expected term of options (in years)     5 years 6 months    
Risk-free interest rate (as a percent)     1.00%    
Minimum          
Fair Value Assumptions          
Expected volatility (as a percent)     75.30%    
Risk-free interest rate (as a percent)     1.02%    
Maximum          
Fair Value Assumptions          
Expected volatility (as a percent)     76.30%    
Risk-free interest rate (as a percent)     1.16%    
Stock Options          
Stock-Based Compensation Expense          
Share-based compensation expense | $ $ 100 $ 51 $ 200 $ 65  
2017 Share Incentive Plan          
Options          
Outstanding at beginning of year (in shares) | shares     442,844    
Forfeited (in shares) | shares     (101,204)    
Outstanding at end of year (in shares) | shares 341,640   341,640    
Vested and exercisable at end of year (in shares) | shares 231,403   231,403    
Weighted average exercise price in $ per share          
Outstanding balance at beginning of year (in dollars per share) | $ / shares     $ 30.89    
Forfeited (in dollars per share) | $ / shares     32.82    
Outstanding balance at end of year (in dollars per share) | $ / shares $ 30.31   30.31    
Vested and exercisable balance at end of year (in dollars per share) | $ / shares $ 34.75   $ 34.75    
2017 Share Incentive Plan | Stock Options          
Fair Value Assumptions          
Weighted-average remaining contractual life     7 years 6 months    
Stock-Based Compensation Expense          
Share-based compensation expense | $ $ 300 500 $ 600 1,100  
Unrecognized compensation expense          
Total unrecognized compensation related to unvested options | $ 1,400   $ 1,400    
Recognition period     1 year 2 months 12 days    
2017 Share Incentive Plan | Restricted Stock Units ("RSUs")          
Share-Based Payments          
Fair Value | $     $ 200    
Stock-Based Compensation Expense          
Share-based compensation expense | $ 100 $ 400 300 $ 1,000  
Unrecognized compensation expense          
Unrecognized compensation costs | $ $ 400   $ 400    
Recognition period     2 years 7 months 6 days    
Restricted Stock Units          
Percentage that vests during the period     25.00%    
Number of shares outstanding | shares     151,269    
Vested and issued | shares     (42,752)    
Forfeited | shares     (30,640)    
Number of shares outstanding | shares 77,877   77,877    
weighted average fair value per share          
Weighted average fair value at the beginning | $ / shares     $ 14.56    
Vested and issued | $ / shares     13.98    
Forfeited | $ / shares     13.62    
Weighted average fair value at the end | $ / shares $ 14.19   $ 14.19    
XENLETA | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs")          
Share-Based Payments          
Number of vesting periods | tranche         3
Vesting period         6 months
XENLETA | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Immediate vesting upon regulatory approval          
Restricted Stock Units          
Percentage that vests during the period         50.00%
XENLETA | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval          
Restricted Stock Units          
Percentage that vests during the period         50.00%
CONTEPO | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Immediate vesting upon regulatory approval          
Restricted Stock Units          
Percentage that vests during the period         50.00%
CONTEPO | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval          
Restricted Stock Units          
Percentage that vests during the period         50.00%